FDA approval decision of a drug for walking disability associated with multiple sclerosis
The FDA will make a decision on the approval of this small-cap company’s drug for walking disability associated with multiple sclerosis on October 22. If approved, this could become a breakthrough treatment for walking disability associated with multiple sclerosis. To find out what the chances are of the drug being approved, how the drug works, what is its sales potential if approved and the potential impact of this FDA decision, read a FREE report at: http://www.newbiomedicine.com
Because you can't count your chickens ? Ive seen a couple of other small cap bio's getting into grief with the FDA at the moment, so you can only start counting the money once the FDA says yes (as opposed to issuing an "approvable letter").
That said, this looks like it'll fly; so I sold all my arms dealing shares and tripled my (long) position here 10 minutes ago.